8-K: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics announces its Q4 and full-year 2024 financial results, highlighting progress in clinical trials for WTX-124 and WTX-330 and providing a business update.

Summary

• Werewolf Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024, along with a business update.
• The company is focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.
• Full enrollment in the cutaneous melanoma dose-expansion arms of the Phase 1/1b clinical trial for WTX-124 is expected by the end of the first half and the second half of 2025 for monotherapy and combination with pembrolizumab, respectively.
• Werewolf plans to meet with the FDA in the second half of 2025 to discuss potential registrational pathways for WTX-124.
• Interim data from the Phase 1/1b clinical trial of WTX-124 is anticipated in the fourth quarter of 2025.
• The company is on track to initiate a Phase 1/2 doseand regimen-finding clinical trial of WTX-330 by the end of the first quarter of 2025.
• As of December 31, 2024, Werewolf had $111.0 million in cash and cash equivalents, which is expected to fund operations through at least the second quarter of 2026.
• The net loss for the fourth quarter of 2024 was $20.4 million, compared to $12.0 million for the same period in 2023.
• The net loss for the full year 2024 was $70.5 million, compared to $37.4 million for the full year 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's progress in clinical trials and a sufficient cash runway, the increased net loss and decreased collaboration revenue raise concerns.

Positives

• WTX-124 has shown promising monotherapy activity and an improved tolerability profile versus high dose IL-2 in heavily pretreated patients.
• One monotherapy and two combination responses continue to demonstrate no evidence of disease progression, with the monotherapy complete response ongoing at greater than one year off therapy.
• The company's cash position of $111.0 million is expected to fund operations through at least the second quarter of 2026.
• The PREDATOR platform continues to demonstrate its effectiveness.

Negatives

• The net loss increased to $70.5 million for the full year 2024, compared to $37.4 million for the full year 2023.
• Collaboration revenue decreased to $1.9 million for the full year 2024, compared to $19.9 million for the same period in 2023 due to the completion of performance obligations under the Jazz Pharmaceuticals agreement.

Risks

• The company's success depends on the successful development and commercialization of its product candidates, which is subject to inherent risks and uncertainties.
• Clinical trial results may not be predictive of future results.
• The company may need to raise additional capital in the future to fund its operations.
• Regulatory approval is not guaranteed and may be delayed or denied.

Future Outlook

The company believes its existing cash and cash equivalents at December 31, 2024 will be sufficient to fund operational expenses and capital expenditure requirements through at least the second quarter of 2026.

Management Comments

• Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, stated that Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor activity and tolerability for cytokine therapeutics.
• He also mentioned that the company expects to build on these promising data in 2025, targeting full enrollment in the monotherapy cutaneous melanoma dose-expansion arm of the WTX-124 Phase 1/1b clinical trial by the end of the first half of 2025, and in combination with pembrolizumab by the end of the year.

Industry Context

Werewolf Therapeutics is operating in the competitive biopharmaceutical industry, focusing on immuno-oncology. The company's approach of developing conditionally activated therapeutics is aimed at improving the safety and efficacy of cytokine therapies, which have shown promise in cancer treatment but are often limited by toxicity.

Comparison to Industry Standards

• Werewolf's approach to cytokine therapy with conditionally activated molecules is similar to that of companies like Compass Therapeutics, which is developing antibody-based therapeutics that target the tumor microenvironment.
• The company's focus on IL-2 and IL-12 INDUKINE molecules is comparable to other companies developing cytokine-based therapies, such as Alkermes with its engineered IL-2 variant, nemvaleukin alfa.
• The reported cash runway through the second quarter of 2026 is a key metric for investors, and it is important to compare this to the cash runway of other similar-stage biopharmaceutical companies.

Stakeholder Impact

• Shareholders: The financial results and clinical trial progress will impact shareholder value.
• Employees: The company's progress and financial stability affect job security and opportunities.
• Patients: Successful development of new therapies could provide new treatment options for cancer patients.

Next Steps

• Full enrollment in the cutaneous melanoma monotherapy dose-expansion arm of the WTX-124 Phase 1/1b clinical trial is expected by the end of the first half of 2025.
• Full enrollment in the cutaneous melanoma dose-expansion arm evaluating WTX-124 in combination with pembrolizumab is expected by the end of 2025.
• The company plans to meet with the FDA in the second half of 2025 to discuss potential registrational pathways for WTX-124.
• Interim data from the Phase 1/1b clinical trial of WTX-124 is anticipated in the fourth quarter of 2025.
• A Phase 1/2 doseand regimen-finding clinical trial of WTX-330 is expected to be initiated by the end of the first quarter of 2025.
• Pending data from Phase 1/2 doseand regimen-finding trial, anticipate opening expansion arms in selected tumor types.

Key Dates